Anne Mcgeorge Sells 7,750 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Anne Mcgeorge sold 7,750 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the sale, the director owned 1,250 shares of the company’s stock, valued at approximately $136,262.50. This trade represents a 86.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $112.41 on Thursday. Dianthus Therapeutics, Inc. has a fifty-two week low of $19.75 and a fifty-two week high of $114.55. The firm has a market capitalization of $6.15 billion, a price-to-earnings ratio of -27.09 and a beta of 1.22. The stock’s 50-day simple moving average is $96.25 and its 200-day simple moving average is $82.21.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, equities analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Elevation Point Wealth Partners LLC purchased a new stake in Dianthus Therapeutics in the second quarter valued at $868,000. Quantbot Technologies LP purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at about $174,000. Emerald Investment Advisers LLC purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at about $2,579,000. E Fund Management Co. Ltd. acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $497,000. Finally, Eagle Health Investments LP acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $12,803,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Trending Headlines about Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains favorable. Truist Financial raised its price target to $128 and maintained a “buy” rating, while the broader analyst consensus is “Moderate Buy” with an average target of $124.27. HC Wainwright also issued an optimistic earnings outlook, potentially supporting DNTH. HC Wainwright earnings outlook
• Positive Sentiment: Institutional ownership trends were generally supportive. AllianceBernstein, Invesco, American Century and Mirae Asset increased their positions during recent quarters, and institutional investors collectively own approximately 47.5% of the company.
• Neutral Sentiment: Short interest was reported at zero shares as of August 11, with a zero-day days-to-cover ratio. This suggests limited short-selling pressure, but also no meaningful short-squeeze catalyst for DNTH.
• Negative Sentiment: Several insiders sold substantial portions of their holdings near $109-$111. SVP Adam M. Veness sold 20,000 shares for approximately $2.21 million, reducing his position by about 81%. Director Anne McGeorge sold 7,750 shares for roughly $845,000, cutting her holdings by 86%, while Director Simon Read sold 2,777 shares for approximately $304,000 and halved his position. The clustered sales may concern investors because they occurred near the stock’s 52-week high. SEC insider trading filing
• Negative Sentiment: Dianthus recently reported a quarterly loss of $0.90 per share, missing the $0.85 consensus estimate. Although revenue of $0.76 million exceeded the $0.30 million forecast, the company remains unprofitable, with analysts expecting a full-year loss of approximately $3.83 per share.

Analysts Set New Price Targets

DNTH has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Truist Financial raised their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. HC Wainwright lifted their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $124.27.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.